Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
Idiopathic pulmonary fibrosis (IPF) is a long-term lung disease that affects an individual's
ability to breathe. In this randomized, double-blind, placebo-controlled trial, we assigned
patients with idiopathic pulmonary fibrosis who had mild-to-moderate lung-function impairment
to one of three groups - receiving a combination of prednisone, azathioprine, and NAC
(combination therapy), NAC alone, or placebo - in a 1:1:1 ratio.